VivoSim Labs, Inc. Common Stock (VIVS) is a publicly traded Healthcare sector company. As of May 21, 2026, VIVS trades at $1.32 with a market cap of $3.68M and a P/E ratio of 0.00. VIVS moved +0.00% today. Year to date, VIVS is -33.33%; over the trailing twelve months it is -35.96%. Its 52-week range spans $1.25 to $5.30. Rallies surfaces VIVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
VivoSim Unveils 96% Accurate AI Diarrhea Prediction Using 3D Intestinal Models: VivoSim’s VitroSense AI tool uses data from its NAMkind ileum and colon models to predict drug-induced diarrhea with 96% accuracy. The platform’s 3D human tissue assays support oral or IV dosing and are now offered globally to screen oncology antibody-drug conjugates for intestinal toxicity.
| Metric | Value |
|---|---|
| Price | $1.32 |
| Market Cap | $3.68M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.30 |
| 52-Week Low | $1.25 |
| Volume | 161.34K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
VIVS analyst coverage data. Average price target: $0.00.